Dharamainder Choudhary1, Poornima Hegde2, Olga Voznesensky3, Shilpa Choudhary3, Stavros Kopsiaftis4, Kevin P Claffey4, Carol C Pilbeam3, John A Taylor5. 1. Department of Surgery, University of Connecticut Health Center, Farmington, CT. 2. Department of Pathology, University of Connecticut Health Center, Farmington, CT. 3. Department of Medicine, University of Connecticut Health Center, Farmington, CT. 4. Department of Cell Biology, University of Connecticut Health Center, Farmington, CT. 5. Department of Surgery, University of Connecticut Health Center, Farmington, CT. Electronic address: jtaylor@uchc.edu.
Abstract
INTRODUCTION: L-Selectin (CD62L) is a vascular adhesion molecule constitutively expressed on leukocytes with a primary function of directing leukocyte migration and homing of lymphocytes to lymph nodes. In a gene expression microarray study comparing laser-captured microdissected high-grade muscle-invasive bladder cancer (MIBC) without prior treatment and low-grade bladder cancer (LGBC) human samples, we found CD62L to be the highest differentially expressed gene. We sought to examine the differential expression of CD62L in MIBCs and its clinical relevance. METHODS: Unfixed fresh and formalin-fixed paraffin-embedded human bladder cancer specimens and serum samples were obtained from the University of Connecticut Health Center tumor bank. Tumor cells were isolated from frozen tumor tissue sections by laser-captured microdissected followed by RNA isolation. Quantitative polymerase chain reaction was used to validate the level of CD62L transcripts. Immunohistochemistry and enzyme-linked immunosorbent assay were performed to evaluate the CD62L protein localization and expression level. Flow cytometry was used to identify the relative number of cells expressing CD62L in fresh tumor tissue. In silico studies were performed using the Oncomine database. RESULTS: Immunostaining showed a uniformly higher expression of CD62L in MIBC specimens vs. LGBCs specimens. Further, CD62L localization was seen in foci of metastatic tumor cells in lymph node specimens from patients with high-grade MIBC and known nodal involvement. Up-regulated expression of CD62L was also observed by flow cytometric analysis of freshly isolated tumor cells from biopsies of high-grade cancers vs. LGBC specimens. Circulating CD62L levels were also found to be higher in serum samples from patients with high-grade metastatic vs. high-grade nonmetastatic MIBC. In addition, in silico analysis of Oncomine Microarray Database showed a significant correlation between CD62L expression and tumor aggressiveness and clinical outcomes. CONCLUSION: These data confirm the expression of CD62L on urothelial carcinoma cells and suggest that CD62L may serve as biomarker to predict the presence of or risk for developing metastatic disease in patients with bladder cancer.
INTRODUCTION:L-Selectin (CD62L) is a vascular adhesion molecule constitutively expressed on leukocytes with a primary function of directing leukocyte migration and homing of lymphocytes to lymph nodes. In a gene expression microarray study comparing laser-captured microdissected high-grade muscle-invasive bladder cancer (MIBC) without prior treatment and low-grade bladder cancer (LGBC) human samples, we found CD62L to be the highest differentially expressed gene. We sought to examine the differential expression of CD62L in MIBCs and its clinical relevance. METHODS: Unfixed fresh and formalin-fixed paraffin-embedded humanbladder cancer specimens and serum samples were obtained from the University of Connecticut Health Center tumor bank. Tumor cells were isolated from frozen tumor tissue sections by laser-captured microdissected followed by RNA isolation. Quantitative polymerase chain reaction was used to validate the level of CD62L transcripts. Immunohistochemistry and enzyme-linked immunosorbent assay were performed to evaluate the CD62L protein localization and expression level. Flow cytometry was used to identify the relative number of cells expressing CD62L in fresh tumor tissue. In silico studies were performed using the Oncomine database. RESULTS: Immunostaining showed a uniformly higher expression of CD62L in MIBC specimens vs. LGBCs specimens. Further, CD62L localization was seen in foci of metastatic tumor cells in lymph node specimens from patients with high-grade MIBC and known nodal involvement. Up-regulated expression of CD62L was also observed by flow cytometric analysis of freshly isolated tumor cells from biopsies of high-grade cancers vs. LGBC specimens. Circulating CD62L levels were also found to be higher in serum samples from patients with high-grade metastatic vs. high-grade nonmetastatic MIBC. In addition, in silico analysis of Oncomine Microarray Database showed a significant correlation between CD62L expression and tumor aggressiveness and clinical outcomes. CONCLUSION: These data confirm the expression of CD62L on urothelial carcinoma cells and suggest that CD62L may serve as biomarker to predict the presence of or risk for developing metastatic disease in patients with bladder cancer.
Authors: Ekaterini Blaveri; Jeff P Simko; James E Korkola; Jeremy L Brewer; Frederick Baehner; Kshama Mehta; Sandy Devries; Theresa Koppie; Sunanda Pejavar; Peter Carroll; Frederic M Waldman Journal: Clin Cancer Res Date: 2005-06-01 Impact factor: 12.531
Authors: Shahrokh F Shariat; Pierre I Karakiewicz; Ganesh S Palapattu; Yair Lotan; Craig G Rogers; Gilad E Amiel; Amnon Vazina; Amit Gupta; Patrick J Bastian; Arthur I Sagalowsky; Mark P Schoenberg; Seth P Lerner Journal: J Urol Date: 2006-12 Impact factor: 7.450
Authors: Nicolas Stransky; Céline Vallot; Fabien Reyal; Isabelle Bernard-Pierrot; Sixtina Gil Diez de Medina; Rick Segraves; Yann de Rycke; Paul Elvin; Andrew Cassidy; Carolyn Spraggon; Alexander Graham; Jennifer Southgate; Bernard Asselain; Yves Allory; Claude C Abbou; Donna G Albertson; Jean Paul Thiery; Dominique K Chopin; Daniel Pinkel; François Radvanyi Journal: Nat Genet Date: 2006-11-12 Impact factor: 38.330
Authors: Ranju Ralhan; Helen C-H He; Anthony K-C So; Satyendra C Tripathi; Manish Kumar; Md Raghibul Hasan; Jatinder Kaur; Lawrence Kashat; Christina MacMillan; Shyam Singh Chauhan; Jeremy L Freeman; Paul G Walfish Journal: PLoS One Date: 2010-11-30 Impact factor: 3.240
Authors: John A Taylor; George A Kuchel; Poornima Hegde; Olga S Voznesensky; Kevin Claffey; John Tsimikas; Lin Leng; Richard Bucala; Carol Pilbeam Journal: BMC Cancer Date: 2007-07-24 Impact factor: 4.430
Authors: Amy W Ku; Jason B Muhitch; Colin A Powers; Michael Diehl; Minhyung Kim; Daniel T Fisher; Anand P Sharda; Virginia K Clements; Kieran O'Loughlin; Hans Minderman; Michelle N Messmer; Jing Ma; Joseph J Skitzki; Douglas A Steeber; Bruce Walcheck; Suzanne Ostrand-Rosenberg; Scott I Abrams; Sharon S Evans Journal: Elife Date: 2016-12-08 Impact factor: 8.140
Authors: Gayatri S Phadke; Jennifer E Satterwhite-Warden; Dharamainder Choudhary; John A Taylor; James F Rusling Journal: Analyst Date: 2018-11-05 Impact factor: 4.616
Authors: Satyajit Mohite; Fang Yang; Pooja A Amin; Giovana Zunta-Soares; Gabriela D Colpo; Laura Stertz; Ajaykumar N Sharma; Gabriel R Fries; Consuelo Walss-Bass; Jair C Soares; Olaoluwa O Okusaga Journal: PLoS One Date: 2017-03-23 Impact factor: 3.240
Authors: Toral P Kobawala; Trupti I Trivedi; Kinjal K Gajjar; Darshita H Patel; Girish H Patel; Nandita R Ghosh Journal: J Thyroid Res Date: 2016-01-11